Secukinumab Approved for Plaque Psoriasis in Children, Adolescents

John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.

Related Videos
Related Content

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

March 20th 2023

The Cutaneous Connection: Diving Into the Aesthetics Industry

February 17th 2022

TMB-001 for Congenital Ichthyosis Subtypes Tested by Dermatologists

March 10th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

March 7th 2023

Recommendations for Treating Oily and Acne-Prone Skin

March 6th 2023

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

March 20th 2023

The Cutaneous Connection: Diving Into the Aesthetics Industry

February 17th 2022

TMB-001 for Congenital Ichthyosis Subtypes Tested by Dermatologists

March 10th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

March 7th 2023

Recommendations for Treating Oily and Acne-Prone Skin

March 6th 2023

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

March 20th 2023

The Cutaneous Connection: Diving Into the Aesthetics Industry

February 17th 2022

TMB-001 for Congenital Ichthyosis Subtypes Tested by Dermatologists

March 10th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

March 7th 2023

Recommendations for Treating Oily and Acne-Prone Skin

March 6th 2023
© 2023 MJH Life Sciences

All rights reserved.